论文部分内容阅读
国内曾有文献综述癌胚抗原(CEA)对肺癌的临床应用价值,也有试用卫生部北京生物制品研究所生产的多克隆抗体CEA-EIA药盒检测肺癌病人血清CEA的报告,其阳性率为68.3％及60.9％。我们采用该所新生产的单克隆抗体CEA-EIA药盒,检测胸腔积液CEA水平,以鉴别原发性肺癌能产生CEA的胸膜转移肿瘤与非肿瘤性胸腔积液的临床意义已作报道,本文报道进一步检测几种不同类型肺癌病人血清CEA的结果及其临床意义。材料和方法本文采用卫生部北京生物制品研究所生
There was a literature review of the clinical value of carcinoembryonic antigen (CEA) for lung cancer, and there was a report of the use of a polyclonal antibody CEA-EIA kit produced by the Beijing Institute of Biological Products of the Ministry of Health to detect serum CEA in patients with lung cancer. The positive rate was 68.3. % and 60.9%. We have used the newly produced monoclonal antibody CEA-EIA kit to detect pleural effusion CEA levels to identify the clinical significance of primary lung cancer can produce CEA pleural metastases and non-neoplastic pleural effusion has been reported. This article reports the further detection of serum CEA in several different types of lung cancer patients and its clinical significance. Materials and Methods This article uses the Beijing Institute of Biological Products, Ministry of Health